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The macrocyclic bisbenzylisoquinoline (BBIQ) alkaloids are among different large classes of alkaloids common in plant species. BBIQ alkaloids are prevalent in the families like Menispermeaceae, Annonaceae, Berberidaceae, Monimaiaceae and Ranunuclaceae. [1] [2] [3] The BBIQ alkaloids were reported to exhibit anti-ovarian, 4-7 -lung, 8 bladder, 9 -colorectal, 10 -gallbladder carcinoma and -prostate 11 cancer activities. 12, 13 The use of isolated natural products as scaffolds to generate their analogues via chemical transformation is a promising and successful approach in drug discovery. 14, 15 So far, only a small number of semi-synthetic BBIQ alkaloids (e.g. tetrandrine and fanginoline analogues, [16] [17] [18] [19] C14-urea-tetrandrine, 20 cycleanine mono-N-oxides, 21 and berbamine derivatives. 22 ) have been made, which show potent cytotoxicity or can reverse P-glycoprotein-mediated multidrug resistance in cancer cells 17, 23 . The making of more potent cytotoxic BBIQ alkaloids with improved activities and investigation of their mechanisms of action (e.g. cellular uptake, target identification) by using the synthetic probes are desired. 24, 25 Previously, several BBIQ alkaloids were isolated from Triclisia subcordata Oliv. by us and they showed potent in vitro anti-ovarian cancer activity. [4] [5] [6] Among them, cycleanine (1) is bioactive, with the highest therapeutic index and the most abundant component (1.1%). 4 Therefore cycleanine was preferred as a hit compound for chemical modification. 14 In this study, we semi-synthesized analogues of cycleanine and evaluated their cytotoxicity, induction of apoptosis, and cellular uptake.
The semi-synthesis of cycleanine analogues was achieved via a simple two-step reaction (Scheme 1). Reaction of cycleanine (1) (Table S1 , Figure S1 and S2), 13 C NMR (Table   S2 ), 2D NMR and high resolution liquid chromatography mass spectrometric (LC-MS)
analysis. The symmetry of cycleanine was lost after the chemical modification, as evidenced by that the single peak for H-5 or 5' in the 1 H NMR of cycleanine 4 was shifted and other peaks for aromatic protons were split into two pairs of peaks (Table S1 , Figure S1 and S2). The resulting single peak around 6.80 ppm in the 1 H NMR of 2 or 3 corresponds to only one proton (H-5') which indicates the substitution at C-5 of cycleanine (1) by the alkylamino groups. The addition of aminoalkyl group to cycleanine could improve its water solubility as found in the approved anticancer drug such as (aminoalkyl)camptothecin (Toptecan). 27, 28 To assay the cytotoxicity or anti-proliferative activities of 2 and 3, the IC 50 of these new compounds were evaluated on different ovarian cancer cell lines (OVCAR-8, A2780 and IGROV-1) and a normal human ovarian epithelial (HOE) cell line after treatment for 72h
using Sulforhodamine B (SRB) colorimetric assay. 29, 30 The results reveal the IC 50 of 2 and 3 ranging from 3.6 ± 0.5 to 5.2 ± 0.6 µM and from 5.6 ± 0.2 to 6.3 ± 0.6 µM, respectively (Table 1 ; Figures S3 and S4 ). The results suggest that 2 and 3, exert about 2-3 times improved potency against three ovarian cancer cells than cycleanine (1) with IC 50 ranging from 7 to 14 µM and the approved anti-ovarian cancer drug-carboplatin with IC 50 ranging from 8 to 16 µM. Cycleanine (1) and 3 seem to be slightly more tolerant to HOE cells than compound 2. Overall, compound 3 showed milder selectivity index (SI) than 1 and 2 ( Table 1) . Table 1 The IC 50 of cycleanine (1) In summary, we have successfully semi-synthesized two novel aminoalkyl BBIQ alkaloids (2 and 3) starting from an isolated natural product-cycleanine through a simple and efficient method of site-specific chemical modification at C-5 position of cycleanine.
The new modification approach has advantages over some reported transformation methods for BBIQ alkaloids. 16, 17, 21 Because it can be applied to cycleanine as well as other BBIQ alkaloids to make a large number of analogues using a range of other nucleophilic compounds (e.g. primary and secondary amines, thiols . The observed anti-proliferative activities and selectivity (Table 1) unmodified cycleanine and other BBIQ alkaloids. 4, 5 Importantly, using analogue 3 appended with a propargyl group its cellular uptake in cancer cells was clearly demonstrated via click chemistry and fluorescence microscopy. The semi-synthesis of additional BBIQ alkaloid analogues using the established approach to gain structureactivity relationship, and identification of protein targets in the cancer cells using a chemical proteomics approach 33, 34 are ongoing in our laboratory. In vivo studies also need to be performed to evaluate the preclinical and clinical effects of these novel compounds.
